The results of these simulations demonstrated a reduction in proinsulin levels without clinically meaningful changes in insulin, glucose, or HbA1c in T2DM VPs (data from VPT2DM-2 shown in Figure 3). This evidence concerns the gene INS and type 2 diabetes mellitus.